213 related articles for article (PubMed ID: 11960345)
41. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
42. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
[TBL] [Abstract][Full Text] [Related]
43. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
44. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
[TBL] [Abstract][Full Text] [Related]
45. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S;
Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704
[TBL] [Abstract][Full Text] [Related]
46. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children.
Kondo M; Kojima S; Horibe K; Kato K; Matsuyama T
Bone Marrow Transplant; 2001 Apr; 27(7):727-30. PubMed ID: 11360113
[TBL] [Abstract][Full Text] [Related]
47. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
48. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
[TBL] [Abstract][Full Text] [Related]
49. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.
Rocha V; Wagner JE; Sobocinski KA; Klein JP; Zhang MJ; Horowitz MM; Gluckman E
N Engl J Med; 2000 Jun; 342(25):1846-54. PubMed ID: 10861319
[TBL] [Abstract][Full Text] [Related]
50. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
[TBL] [Abstract][Full Text] [Related]
51. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M
J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108
[TBL] [Abstract][Full Text] [Related]
52. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
[TBL] [Abstract][Full Text] [Related]
53. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
54. [Allogeneic hematopoietic stem cell transplantation for acute lymphocytic leukemia].
Chen H; Ren HY; Guo NL; Huang XJ; Liu KY; Xu LP; Zhang YC; Zheng H; Wu T; Liu DH; Yang SM; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):87-90. PubMed ID: 14990046
[TBL] [Abstract][Full Text] [Related]
55. Outcomes of immunological interventions for mixed chimerism following allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
Inagaki J; Fukano R; Nishikawa T; Nakashima K; Sawa D; Ito N; Okamura J
Pediatr Blood Cancer; 2013 Jan; 60(1):116-20. PubMed ID: 22847790
[TBL] [Abstract][Full Text] [Related]
56. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia.
Kerbauy DM; Chyou F; Gooley T; Sorror ML; Scott B; Pagel JM; Myerson D; Appelbaum FR; Storb R; Deeg HJ
Biol Blood Marrow Transplant; 2005 Sep; 11(9):713-20. PubMed ID: 16125642
[TBL] [Abstract][Full Text] [Related]
57. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML).
Hasle H; Baumann I; Bergsträsser E; Fenu S; Fischer A; Kardos G; Kerndrup G; Locatelli F; Rogge T; Schultz KR; Starý J; Trebo M; van den Heuvel-Eibrink MM; Harbott J; Nöllke P; Niemeyer CM;
Leukemia; 2004 Dec; 18(12):2008-14. PubMed ID: 15496981
[TBL] [Abstract][Full Text] [Related]
58. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients.
Korthof ET; Snijder PP; de Graaff AA; Lankester AC; Bredius RG; Ball LM; Lie JL; Vossen JM; Egeler RM
Bone Marrow Transplant; 2005 Mar; 35(5):455-61. PubMed ID: 15654356
[TBL] [Abstract][Full Text] [Related]
59. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia.
Smith FO; King R; Nelson G; Wagner JE; Robertson KA; Sanders JE; Bunin N; Emaunel PD; Davies SM;
Br J Haematol; 2002 Mar; 116(3):716-24. PubMed ID: 11849238
[TBL] [Abstract][Full Text] [Related]
60. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience.
Yusuf U; Frangoul HA; Gooley TA; Woolfrey AE; Carpenter PA; Andrews RG; Deeg HJ; Appelbaum FR; Anasetti C; Storb R; Sanders JE
Bone Marrow Transplant; 2004 Apr; 33(8):805-14. PubMed ID: 14755311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
